Journal article
Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C
Journal of clinical gastroenterology, v 53(2), pp 147-154
01 Feb 2019
PMID: 29912759
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Background: Limited data exist with regard to treatment outcomes in Asian Americans with chronic hepatitis C (CHC). We evaluated sofosbuvir (SOF)-based regimens in a national cohort of Asian Americans. Methods: Eligible Asian Americans patients with CHC who had posttreatment follow-up of 24 weeks for SOF -based therapies from December 2013 to June 2017 were enrolled from 11 sites across the United States. The primary endpoint was sustained virologic response (SVR) rates at posttreatment weeks 12 and 24. Secondary endpoints were to evaluate safety by tolerability and adverse events (AEs). Results: Among 231 patients screened, 186 were enrolled. At baseline, 31% (57/186) patients were cirrhotic, 34% (63/186) were treatment experienced. Most of the subjects (42%, 79/186) received ledispavir/SOF therapy. The overall SVR12 was 95%, ranging from 86% in genotype (GT) 1b on SOF+ribavirin to 100% in GT 1b patients on ledipasvir/SOF at subgroup analyses. SVR12 was significantly lower in cirrhotic than in noncirrhotic patients [88% (50/57) vs. 98% (126/129), P<0.01]. Stratified by GT, SVR12 were: 96% (43/45) in GT 1a; 93% (67/72) in GT 1b; 100% (23/23) in GT 2; 90% (19/21) in GT 3; 100% (1/1) in GT 4; 83% (5/6) in GT 5; and 100% (16/16) in GT 6. Cirrhotic patients with treatment failure were primarily GT 1, (GT 1a, n=2; GT 1b, n=4) with 1 GT 5 (n=1). Patients tolerated the treatment without serious AEs. Late relapse occurred in 1 patient after achieving SVR12. Conclusions: In Asian Americans with CHC, SOF-based regimens were well tolerated without serious AEs and could achieve high SVR12 regardless of hepatitis C viral infection GT.
Metrics
Details
- Title
- Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C
- Creators
- Calvin Q. Pan - Department of Medicine, Division of Gastroenterology and Hepatology, NYU Langone Health, NYU School of Medicine.Benjamin C. Tiongson - Interfaith Medical CenterKe-Qin Hu - University of California, IrvineSteven-Huy B. Han - Univ Calif Los Angeles, David Geffen Sch Med, Pfleger Liver Inst, Los Angeles, CA 90095 USAMyron Tong - Huntington Medical Research InstitutesDanny Chu - Lower Manhattan HospitalJames Park - Department of Medicine, Division of Gastroenterology and Hepatology, NYU Langone Health, NYU School of Medicine.Tai Ping Lee - Hofstra UniversityKalyan Ram Bhamidimarri - University of MiamiXiaoli Ma - Hahnemann University HospitalPei Ying Xiao - SUNY Downstate Medical CenterSmruti R. Mohanty - NewYork–Presbyterian Brooklyn Methodist HospitalDan Wang - College of Saint Benedict and Saint John's University
- Publication Details
- Journal of clinical gastroenterology, v 53(2), pp 147-154
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 8
- Grant note
- Gilead Sciences Inc.; Gilead Sciences
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Medicine (Graduate)
- Web of Science ID
- WOS:000458415900016
- Scopus ID
- 2-s2.0-85048614253
- Other Identifier
- 991019167667804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Gastroenterology & Hepatology